Tumor necrosis factor (TNF) is a major inflammatory cytokine, secreted primarily by activated macrophages and T lymphocytes, that is thought to limit infections by a variety of microorganisms (reviewed in reference 68). In cultured cells infected with different RNA and DNA viruses, TNF inhibits virus replication or induces apoptosis (reviewed in references 21 and 79) . Some viruses, in turn, have evolved strategies to block the antiviral effects of TNF (reviewed in references 11, 20, 47, 58, 68, 73, and 76-79) . For example, poxviruses secrete TNF receptor homologs that bind TNF and presumably preclude TNF function (reviewed in reference 60).
Human adenoviruses (Ad) encode five proteins that modulate the effects of TNF (reviewed in references 20, 47, and 76-79) . In contrast to poxviruses, the Ad proteins remain within the cell and therefore are useful tools to probe the cellular biology of TNF function. TNF induces apoptosis in a minority of tumor cell lines, but most cell types are resistant to TNF. Ad-infected cells are resistant to TNF, but they are lysed by TNF when infected with Ad mutants lacking certain genes (22) . The Ad E1A proteins sensitize cells to TNF (7, 17, 59) , and three sets of Ad proteins inhibit TNF-induced apoptosis (22-24, 33, 55) . Two of these sets are encoded by the Ad E3 transcription unit: a 14,700-kDa protein named E3-14.7K (67) and a complex of two proteins of 10,400 and 14,500 kDa named E3-10.4K/14.5K (64, 65) . The third TNF-negating protein, coded by the E1B transcription unit, is E1B-19K (21, 74) .
The mechanisms of TNF-induced apoptosis and its inhibition by the Ad proteins are poorly understood. In most cell types, TNF induces apoptosis via the p55 TNF receptor (TNFR1) (reviewed in references 3, 12, 28, 69, 73) . TNFinduced apoptosis requires the activation of one or more of the interleukin-1␤ (IL-1␤) converting enzymes that function in apoptosis (reviewed in reference 29) . There is also considerable evidence that TNF activation of the 85-kDa cytosolic phospholipase A 2 (cPLA 2 ) is necessary but not sufficient for TNF-induced apoptosis (27, 72 ; reviewed in references 28 and 41) . cPLA 2 can be activated by phosphorylation by mitogenactivated protein kinase (MAPK) (1, 14, 50, 52, 54, 56) . Studies in vitro have shown that in the presence of submicromolar Ca 2ϩ , cPLA 2 translocates to membranes where it cleaves arachidonic acid (AA) specifically from the sn-2 position of membrane phospholipids (6, 10, 51) . In vivo, cPLA 2 activity is induced by many agonists, including IL-1␤, platelet-derived growth factor (PDGF) (48) (49) (50) , and TNF (27, 31, 72) . TNFinduced release of AA and TNF-induced apoptosis, which require cPLA 2 , are coordinately inhibited by E3-10.4K/14.5K and E3-14.7K, each able to act independently, in Ad-infected mouse cells (41) . E3-14.7K also inhibits TNF-induced AA release and apoptosis in stably transfected mouse (41, 81) and human (30) cells. E1B-19K inhibits TNF-induced apoptosis in transfected human cells (74) .
E1B-19K localizes primarily to the nuclear membrane and is considered to be a functional homolog of Bcl-2 (8, 63; reviewed in reference 73). Bcl-2 is a modest inhibitor of TNF-induced apoptosis (8, 36) . E3-14.7K is a hydrophilic nonmembrane protein (30) that may function at or upstream of the proteolytic events that occur early in apoptosis (71) . E3-10.4K/14.5K is an integral membrane protein complex (42, 43) that is localized in many cellular membranes, including the plasma membrane (32, 62, 66) . E3-14.5K is phosphorylated on serine (45) , and it is O glycosylated (44) .
As judged by in vitro studies, agonists that activate cPLA 2 to release AA should not only phosphorylate cPLA 2 but they should also induce translocation of cPLA 2 from the cytosol to membranes in vivo. However, to our knowledge, translocation of cPLA 2 to membranes has only actually been shown in response to the Ca 2ϩ ionophore A23187 (several cell types), basic fibroblast growth factor (endothelial cells), formylmethionyl (fMet)-Leu-Phe (neutrophils), immunoglobulin E-antigen (mast cells), and transforming growth factor ␣ (keratinocytes) (18, 19, 39, 53, 56, 57) . Here we report that TNF, IL-1␤, PDGF, and cycloheximide (CHX), as well as A23187, induce translocation of cPLA 2 from the cytosol to membranes in A549 human alveolar epithelial carcinoma cells. Interestingly, E3-10.4K/14.5K, but not E3-14.7K or E1B-19K, is required to prevent TNF-induced translocation of cPLA 2 to membranes in Ad-infected A549 cells. This may explain how E3-10.4K/14.5K inhibits TNF-induced AA release and apoptosis. Ad infection also inhibited cPLA 2 translocation to membranes in response to CHX and A23187, but this inhibition did not require E3-10.4K/14.5K.
For immunoblots, membrane pellets were solubilized in 2ϫ Laemmli buffer, subjected to SDS-PAGE as described above, and then transferred to Immobilon D (Millipore) membranes for 30 min with a Trans-Blot (Bio-Rad) semidry apparatus. Mouse monoclonal antibody against cPLA 2 (a gift from the Genetics Institute) was used at a dilution of 1:1,000. The second antibody, rabbit antimouse immunoglobulin G conjugated to horseradish peroxidase (Amersham Life Sciences), was used at a dilution of 1:3,000. cPLA 2 was visualized with an ECL kit (Amersham Life Sciences).
Analysis of TNF-induced SDS-PAGE mobility shift of cPLA 2 . Cells at 8 h p.i. were treated with TNF for 15 min, washed twice with phosphate-buffered saline, and then lysed in boiling hot 2ϫ Laemmli buffer (200 l of buffer per 30-mmdiameter dish). The cells were subjected to four cycles of boiling and vigorous mixing to reduce viscosity, and then 20 l was loaded onto a 20-cm-long 7.0% polyacrylamide gel (acrylamide: N,NЈ-methylenebisacrylamide, 60:1, wt/wt). The samples were subjected to SDS-PAGE; electrophoresis was terminated 4 h after the tracking dye had run off the bottom of the gel. cPLA 2 was detected by immunoblotting as described above.
[ 3 H]AA release. Cells were labeled for 18 h in Dulbecco's minimal essential medium containing 10% fetal calf serum and 0.5 Ci of [5,6,8,12,14,15- 3 H]AA (180 to 240 Ci/mmol; NEN Dupont) per ml. The cells were washed, infected with Ad, and treated with TNF at 8 h p.i., and then [ 3 H]AA released into the culture supernatant was counted.
EMSA for NFB. Mock-or virus-infected cells were untreated or treated with TNF at 8 h p.i. After 1 h, cytosol and membrane fractions were prepared. The cytosol was assayed for NFB binding activity by electrophoretic mobility shift assay (EMSA) as described previously (16) . Typically, 2 l of cell lysate was incubated in 20 l of HDKE buffer (20 mM HEPES [pH 7.9], 50 mM KCl, 1.0 mM EDTA, 5% glycerol) containing 1 g of poly(dI-dC) per l for 10 min at room temperature prior to the addition of 10 5 cpm of 32 P-labeled oligonucleotide no. 1. After 10 min, bound DNA was separated from free DNA by electrophoresis through a 4% native polyacrylamide gel and visualized by autoradiography. For the competition experiments, a 100-fold molar excess of unlabeled oligonucleotides was added to the samples for 10 min prior to the addition of the 32 P-labeled oligonucleotide. 
The following E3 proteins are expressed by rec700, Ad5, and Ad2: 12.5K, 6.7K, gp19K, ADP, 10.4K, 14.5K, and 14.7K. Phenotype symbols are explained in footnote c.
b rec700 is an Ad5-Ad2-Ad5 recombinant which is the parental virus for dl748, dl753, dl759, dl764, dl763, dl762, dl798, pm760, dl7001, and dl7000. c E3-10.4K and E3-14.5K are both encoded by E3 mRNA f, and E3-14.7K is encoded by E3 mRNA h (8, 78) . Some of the mutations in the mutants in this table affect alternative splicing of E3 mRNAs such that mRNAs f and h, as well as other E3 mRNAs, and the proteins they encode, are overproduced or underproduced. Also, some of the deletions mutate the gene so that the protein cannot be produced. For example, dl748 greatly overproduces mRNA f and underproduces all other E3 mRNAs, and it has a deletion in the gene for E3-10.4K; thus, E3-10.4K is not made, E3-14.5K is greatly overproduced, and the other E3 proteins are barely detectable (64, 65) . The relative levels of the E3 proteins synthesized by these mutants are indicated by the number of plus signs. dl798 overexpresses E3-10.4K, but it does not express E3-14.5K. pm760 overexpresses both E3-10.4K and E3-14.5K.
d Ad5 is the parental virus for dl309 and dl111. e dl111 has the same E3 deletion as dl309, and it does not express E1B-19K. f dl7001 deletes all E3 genes, and dl7000 deletes all E3 genes except that for E3-14.7K.
The sequences of the oligonucleotides, with the NFB motif underlined, are as follows (the oligonucleotides are duplex; only the 5Ј33Ј strand is shown): oligonucleotide no. 1, 5Ј-TCGAGGGGAATTCCCGTCGA-3Ј; oligonucleotide no. 2, 5Ј-CCGAACATTGCACAATCTGGGAATTCCCCCGA-3Ј; oligonucleotide no. 3, 5Ј-CCGAACATTGCACAATCTATCTATCTCCCCGA-3Ј; oligonucleotide no. 4, 5Ј-CCGAACACTACAAACTCTGGGAATTCCCCCGA-3Ј.
RESULTS
Ad E3-10.4K/14.5K protein complex is required to inhibit TNF-induced translocation of cPLA 2 to membranes. cPLA 2 -induced cleavage of AA occurs when cPLA 2 is phosphorylated by MAPK and is translocated from the cytosol to membranes in the presence of small amounts of Ca 2ϩ . As shown in Fig. 1A , cPLA 2 was not detectable by immunoblotting in the membrane fraction from A549 cells that were mock infected (lane a) or infected with rec700 (wild-type Ad) (lane b). Treatment with TNF for 30 min caused cPLA 2 to translocate to membranes (Fig. 1A, lane c) . TNF-induced translocation of cPLA 2 was blocked in cells infected with rec700 (Fig. 1A, lane d) but not with dl763, a mutant that lacks E3-14.5K and E3-14.7K (Fig.  1A , lane e). When both the cytosol and membrane fractions were examined, neither TNF, CHX (which sensitizes cells to TNF), nor rec700 markedly affected cPLA 2 levels in the cytosol (Fig. 1B, lanes a to d) . However, rec700 inhibited translocation to membranes when cells were treated with TNF alone (Fig.  1B, lane g ) or TNF plus CHX (Fig. 1B, lane h) . These results indicate that TNF induces translocation of cPLA 2 from the cytosol to membranes; that neither TNF, rec700, nor CHX markedly affects the total amount of cPLA 2 in the cell; that wild-type rec700 blocks TNF-induced translocation of cPLA 2 to membranes; that E3 proteins deleted from dl763 (14.5K and 14.7K) are required to inhibit TNF-induced translocation of cPLA 2 ; and that E1B-19K, which is expressed by dl763 (data not shown), does not block TNF-induced translocation of cPLA 2 .
The kinetics of TNF-induced translocation of cPLA 2 to membranes were examined, in this case by metabolically labeling cPLA 2 with Na 3 32 PO 4 and then immunoprecipitating 32 Plabeled cPLA 2 from the membrane fraction. Latent inactive cPLA 2 is phosphorylated at multiple sites by unknown kinases (15, 54) , so this experiment measures total translocated cPLA 2 , not simply cPLA 2 that has been phosphorylated in response to TNF. (Neither Ad infection nor TNF treatment markedly affected the bulk of total cellular cPLA 2 that was metabolically labeled with Na 3 32 PO 4 under these conditions; see Fig. 7 .) TNF-induced translocation of [ 32 P]cPLA 2 was barely detectable after 10 min of TNF treatment, was obvious after 20 min, continued to increase until 120 min (Fig. 2, lanes a, c, e , g, and i), and was still apparent after 6 h (data not shown). Translocation of [ 32 P]cPLA 2 was not observed in rec700-infected cells at 10 to 120 min following TNF treatment (Fig. 2, lanes b, d, 
Selected Ad mutants were used to further examine the E3 genes responsible for blocking TNF-induced translocation of cPLA 2 to membranes (the E3 proteins expressed by these mutants are indicated in Table 1 ). As expected, TNF-induced translocation of [ 32 P]cPLA 2 was not inhibited by dl7001, a mutant that lacks all E3 genes (Fig. 3A, lane d) . E3-14.7K is one of the proteins that inhibits TNF-induced release of AA and apoptosis (22, 23, 24, 33, 41, 55, 81) . However, E3-14.7K is not required to inhibit cPLA 2 translocation, because translocation was inhibited with dl762 which lacks only 14.7K, and it was not inhibited with dl7000 in which 14.7K is the only E3 3B, lane b) , establishing that this property is not unique to rec700, an Ad5-Ad2-Ad5 recombinant. As expected, inhibition was not observed with the Ad5 mutant dl309, which lacks the E3 10.4K, 14.5K, and 14.7K proteins (4) (Fig. 3B, lane c) , nor was inhibition observed with dl111, which lacks the same E3 genes as dl309 and also lacks E1B-19K (2) (Fig. 3B, lane d) .
Additional mutants were used to establish more precisely which E3 proteins are required to inhibit TNF-induced translocation of cPLA 2 . As shown in Fig. 4A , TNF-induced [ 32 P] cPLA 2 translocation (lane h) was prevented by rec700 (lane g) and pm760 (lane d), a mutant that markedly overproduces E3-10.4K and E3-14.5K and underproduces all other E3 proteins (64) . Translocation of cPLA 2 was not inhibited by dl759 or dl798, mutants that express E3-10.4K but not E3-14.5K, or by dl748 or dl753, mutants that express E3-14.5K but not E3-10.4K. dl759 and dl753 express all other E3 proteins at wildtype levels, so E3 proteins other than E3-10.4K and E3-14.5K do not prevent translocation of cPLA 2 . When cells were coinfected with dl798 (which provides E3-10.4K) and dl748 (which provides E3-14.5K), translocation of cPLA 2 was blocked (Fig.  4A, lane f) ; this indicates that dl798 and dl748 complement and that both E3-10.4K and E3-14.5K are required to inhibit translocation of cPLA 2 .
As a further test of this conclusion, we examined an A549 cell line (A549/14.5K) stably transfected with the gene for E3-14.5K. These cells were confirmed by immunoprecipitation to express E3-14.5K (data not shown). TNF-induced translocation of [ 32 P]cPLA 2 was not prevented in the A549/14.5K cell line (Fig. 4A, lane i) . However, when these cells were infected with dl798 (10.4K ϩ and 14.5K Ϫ ), in which the cells provide E3-14.5K and dl798 provides E3-10.4K, cPLA 2 translocation was nearly completely blocked (Fig. 5C ). This result indicates again that E3-10.4K and E3-14.5K function in concert to inhibit TNF-induced translocation of cPLA 2 .
If rec700 inhibits TNF-induced translocation of cPLA 2 (Fig. 5) . We have shown previously that mutants which lack the E3-10.4K, E3-14.5K, and E3-14.7K proteins do not inhibit TNF-induced release of AA (41) .
The ability of Ad to inhibit translocation of cPLA 2 to membranes induced by several other agonists was examined. As shown in Fig. 6A (Fig. 6B, lanes f to h) or CHX (lanes l to n) but not that induced by TNF (lanes i to k). Thus, E3-10.4K/14.5K is required to block cPLA 2 translocation in response to TNF but not in response to A23187 or CHX.
Ad infection does not inhibit TNF-induced phosphorylation of cPLA 2 or activation of NFB. cPLA 2 is phosphorylated at multiple sites (15, 54) . To assess how TNF treatment and Ad infection affect the phosphorylation of cPLA 2 , cells were infected with rec700 or dl763 (14.5K Ϫ and 14.7K Ϫ ), labeled for 6 h with Na 3 32 PO 4 , and treated or not treated with TNF, and cPLA 2 was immunoprecipitated from the membrane and cytosol fractions. The total amounts of [ 32 P]cPLA 2 in the membrane-plus-cytosol extract from each infection appeared to be roughly similar, e.g., the amount of cPLA 2 in lane a of Fig. 7B is similar to the sum of the cPLA 2 in lanes b of Fig. 7A and B. Thus, neither TNF treatment nor Ad infection markedly affects the bulk of cPLA 2 that can be metabolically labeled with Na 3 32 PO 4 . Phosphorylation of cPLA 2 on serine 505 by MAPK is reported to decrease the mobility of cPLA 2 in SDS-PAGE (1, 50, 52). Indeed, two bands of cPLA 2 could be resolved on a 20-cm-long gel with a 60:1 ratio of acrylamide to bisacrylamide (Fig. 8, lane b) . Most of the cPLA 2 in untreated cells migrated as the slower band. TNF treatment shifted all of the cPLA 2 to the slower band (Fig. 8, lane c) ; this shift was not affected by rec700 infection (lane d). These results provide indirect evidence that TNF induces phosphorylation of cPLA 2 , perhaps on serine 505, and that this phosphorylation is not affected by Ad infection. The observation that TNF induces a relatively small fraction of cPLA 2 to the slower-migrating form (Fig. 8) is consistent with the observation that TNF does not markedly increase the metabolic labeling of cPLA 2 with Na 3 32 PO 4 (Fig.  7) .
The results in Fig. 8 indicate that Ad infection does not inhibit all aspects of TNF signal transduction. As an alternative means to address this question, TNF activation of NFB was examined by EMSA at 8 h p.i. As shown in Fig. 9 8 . rec700 does not inhibit TNF-induced mobility shift of cPLA 2 in SDS-PAGE. Mock-or rec700-infected cells were treated with TNF for 15 min at 8 h p.i., and then total cellular cPLA 2 was examined by immunoblotting with a 20-cm gel with an acrylamide/bisacrylamide ratio of 60:1. The upper band has been reported to be diagnostic of phosphorylation of cPLA 2 on serine 505, an event that increases the activity of cPLA 2 .
FIG. 9. rec700 and dl763 do not inhibit TNF activation of NFB. Mock-or virus-infected cells were treated with TNF from 8 to 9 h p.i. and then fractionated into cytosol and membranes. The cytosol was assayed for NFB activity by EMSA. In lanes f to i, unlabeled oligonucleotides that do or do not contain binding motifs for the NFB and C/EBP transcription factors were used (see Materials and Methods). Competition was observed with oligonucleotides no. 1, 2, and 4, which contain the NFB motif. In the membrane fraction, rec700 but not dl763 (14 2 . TNF activation of cPLA 2 activity to generate AA from membrane phospholipids is necessary but not sufficient for TNF-induced apoptosis. For most agonists, it is believed that synthesis of AA by cPLA 2 requires that cPLA 2 be activated by phosphorylation, perhaps on serine 505 by MAPK, and that cPLA 2 translocate to membranes in a Ca 2ϩ -dependent manner (6, 10, 19, (50) (51) (52) 57) . In this report, we have shown that TNF induces translocation of cPLA 2 from the cytosol to membranes. We have also established that E3-10.4K/14.5K, but not E3-14.7K or E1B-19K, is required to inhibit TNF-induced translocation of cPLA 2 to membranes in human A549 cells infected with Ad mutants lacking these proteins. Thus, E3-10.4K/14.5K may block TNF-induced AA release and apoptosis by preventing translocation of activated cPLA 2 to membranes.
In addition to TNF, we have shown that IL-1␤, PDGF, and A23187 induce cPLA 2 translocation to membranes in vivo. This is expected because these agents induce AA release. We have also shown that CHX induces cPLA 2 translocation; CHX does not induce significant AA release (41, 81) , so a second event, perhaps phosphorylation, must be required to activate cPLA 2 . Ca 2ϩ is required for cPLA 2 to associate with membranes in vitro, and A23187 induces cPLA 2 translocation in vivo. Phosphorylation by MAPK is not required for cPLA 2 translocation in vivo (57) or in vitro (10, 51) . Thus, TNF, IL-1␤, PDGF, and CHX probably induce cPLA 2 translocation by mobilizing the submicromolar amounts of Ca 2ϩ that are required for cPLA 2 translocation to occur. Ad infection inhibited cPLA 2 translocation in response to A23187 and CHX; we are attempting to identify the Ad genes responsible for this inhibition.
It is unlikely that E3-10.4K/14.5K inhibits the actual cPLA 2 translocation step, because Ad infection did not inhibit cPLA 2 translocation in response to IL-1␤ or PDGF. Considering that Ca 2ϩ but not phosphorylation is required for translocation of cPLA 2 , our results could be interpreted to indicate that E3-10.4K/14.5K inhibits TNF-induced increase in intracellular Ca 2ϩ . If so, then E3-10.4K/14.5K could function anywhere in the signal transduction pathway from the TNF receptor to this putative TNF-specific Ca 2ϩ channel. There are two receptors for TNF, TNFR1 and TNFR2. Most aspects of signal transduction in nonhematopoietic cells, including apoptosis and activation of NFB, occur via TNFR1 (reviewed in reference 28). E3-10.4K/14.5K is known to stimulate the endosome-mediated internalization and degradation of the receptors for epidermal growth factor (5, 66), insulin, and insulin-like growth factor 1 (46). We do not know whether E3-10.4K/14.5K also down-regulates TNFR1 or TNFR2. If so, this probably does not explain the ability of E3-10.4K/14.5K to inhibit cPLA 2 translocation, because such inhibition was observed in cells where TNF was able to induce phosphorylation of cPLA 2 and to activate NFB. Ad infection also did not inhibit TNF-induced activation of NFB in mouse L929 cells (30) .
Interaction of TNF with TNFR1 induces oligomerization of the receptor and binding of several proteins to the receptor (reviewed in reference 3). TRADD binds the receptor, and FADD, TRAF2, and RIP bind TRADD. TNFR1-TRADD-FADD complexes signal apoptosis, and TNFR1-TRADD-TRAF2 complexes activate NFB (35) . TNFR1-TRADD-RIP complexes induce both apoptosis and NFB activation (34) . The mechanisms by which these protein complexes signal are unknown. One possibility is that sphingomyelinases are activated by TNF to generate ceramide, which acts as a second messenger (reviewed in references 26 and 40). Neutral and acidic sphingomyelinases reportedly are involved in apoptosis and NFB activation (75) . Ceramide activates a ceramideactivated protein phosphatase which may indirectly induce apoptosis (26) . Ceramide also activates ceramide-activated protein kinase (40) . All of these proteins are associated with membranes, and therefore, inhibition of any of their activities could be the mechanism by which the E3-10.4K/14.5K integral membrane protein complex blocks cPLA 2 translocation.
TNF modestly activates MAPK, but it strongly activates the stress-induced pathways where c-Jun kinase and a p38 kinase play a role analogous to that of MAPK (reviewed in references 13 and 38). These stress pathways have been implicated in apoptosis (70, 80) . However, it is not known whether these pathways are affected by E3-10.4K/14.5K.
Mice infected in the lung with Ad suffer a modest inflammatory response which is dramatically enhanced with Ad mutants that lack both E3-10.4K/14.5K and E3-14.7K (61) . Expression of either E3-10.4K/14.5K or E3-14.7K is sufficient to give a wild-type phenotype. AA generated by cPLA 2 can be metabolized to the proinflammatory prostaglandins and leukotrienes. Thus, E3-10.4K/14.5K may inhibit not only apoptosis but also inflammation in Ad infections by inhibiting TNFinduced translocation of cPLA 2 to membranes.
